Toceranib

Toceranib

Clinical data
Trade names	Palladia
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
ATCvet code	Template:Infobox drug/formatATCvet Template:Infobox drug/formatATCvet
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	77%
Protein binding	91%-93%
Elimination half-life	16 h
Identifiers
IUPAC name 5-[(5Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(pyrrolidin-1-yl)ethyl]-1H-pyrrole-3-carboxamide
CAS Number	356068-94-5
PubChem CID	8034466
ChemSpider	4486268
UNII	59L7Y0530C
ChEMBL	ChEMBL13608
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C22H25FN4O2
Molar mass	396.46 g/mol 494.46 g/mol (phosphate)
3D model (JSmol)	Interactive image
SMILES Fc1ccc2c(c1)/C(C(=O)N2)=C/c4c(c(C(=O)NCCN3CCCC3)c(n4)C)C

WikiDoc Resources for Toceranib
Articles
Most recent articles on Toceranib Most cited articles on Toceranib Review articles on Toceranib Articles on Toceranib in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Toceranib Images of Toceranib Photos of Toceranib Podcasts & MP3s on Toceranib Videos on Toceranib
Evidence Based Medicine
Cochrane Collaboration on Toceranib Bandolier on Toceranib TRIP on Toceranib
Clinical Trials
Ongoing Trials on Toceranib at Clinical Trials.gov Trial results on Toceranib Clinical Trials on Toceranib at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Toceranib NICE Guidance on Toceranib NHS PRODIGY Guidance FDA on Toceranib CDC on Toceranib
Books
Books on Toceranib
News
Toceranib in the news Be alerted to news on Toceranib News trends on Toceranib
Commentary
Blogs on Toceranib
Definitions
Definitions of Toceranib
Patient Resources / Community
Patient resources on Toceranib Discussion groups on Toceranib Patient Handouts on Toceranib Directions to Hospitals Treating Toceranib Risk calculators and risk factors for Toceranib
Healthcare Provider Resources
Symptoms of Toceranib Causes & Risk Factors for Toceranib Diagnostic studies for Toceranib Treatment of Toceranib
Continuing Medical Education (CME)
CME Programs on Toceranib
International
Toceranib en Espanol Toceranib en Francais
Business
Toceranib in the Marketplace Patents on Toceranib
Experimental / Informatics
List of terms related to Toceranib

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Toceranib is a receptor tyrosine kinase inhibitor and is used in the treatment of canine mast cell tumor also called mastocytoma. Together with masitinib (Kinavet (US)/Masivet (EU/ROW) by AB Science), toceranib is the only dog-specific anti-cancer drug approved by the U.S. Food and Drug Administration. It is marketed as Palladia as its phosphate salt, toceranib phosphate (INN) by Pfizer. It was developed by SUGEN as SU11654, a sister compound to sunitinib, which was later approved for human therapies. Toceranib is likely to act mostly through inhibition of the kit tyrosine kinase, though it may also have an anti-angiogenic effect.

External links

• Official Site for Palladia